Chinese herbal medicine (zi shen qing) for mild-to-moderate systematic lupus erythematosus: A pilot prospective, single-blinded, randomized controlled Study

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Zhong, Linda L D ^a   Bian, Zhao Xiang ^a   Gu, Jun Hua ^b   Zhou, Xin ^b   Tian, Yu ^b   Mao, Jian Chun ^b   Chen, Xiang Jun ^b  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; HERBACEOUS AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; UNCLASSIFIED DRUG; ZI SHEN QING;

ADOLESCENT; ADULT; AGED; BLOOD CELL COUNT; CHILD; CHINESE; CHINESE MEDICINE; CHINESE MEDICINE SYNDROMES; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; EPIGASTRIC PAIN; FEMALE; HUMAN; INCIDENCE; INFECTION; INSOMNIA; KIDNEY FUNCTION; LIVER FUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHOOL CHILD; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION;

EID: 84878686345     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/327245     Document Type: Review

References (52)

1. Stoll T., Sutcliffe N., Mach J., Klaghofer R., Isenberg D. A., Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus: a 5-year prospective study. Rheumatology 2004 43 8 1039 1044 2-s2.0-4243120895 10.1093/rheumatology/keh238 (Pubitemid 39144453)
2. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines, Guidelines for referral and management of systemiclupus erythematosus in adults. Arthritis & Rheumatism 1999 42 9 1785 1796
3. Nossent J., Kiss E., Rozman B., Pokorny G., Vlachoyiannopoulos P., Olesinska M., Marchesoni A., Mosca M., Påi S., Manger K., Schneider M., Nielsen H., Van Vollenhoven R., Swaak T., Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010 19 8 949 956 2-s2.0-77954074375 10.1177/0961203310366572
4. Klippel J., Primer on the Rheumatic Diseases 1997 11th Atlanta, Ga, USA Arthritis Foundation
5. Font J., Cervera R., Ramos-Casals M., García-Carrasco M., Sentís J., Herrero C., Del Olmo J. A., Darnell A., Ingelmo M., Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Seminars in Arthritis and Rheumatism 2004 33 4 217 230 2-s2.0-1442348282 10.1053/S0049-0172(03)00133-1 (Pubitemid 38280821)
6. Firestein G. S., Kelley's Textbook of Rheumatologyed 2008 8th Philadelphia, Pa, USA Saunders
7. Mak A., Isenberg D. A., Lau C. S., Global trends, potential mechanisms and early detection of organ damage in SLE. Nature Reviews. Rheumatology 2012 10.1038/nrrheum.2012.208
8. Doria A., Iaccarino L., Ghirardello A., Zampieri S., Arienti S., Sarzi-Puttini P., Atzeni F., Piccoli A., Todesco S., Long-term prognosis and causes of death in systemic lupus erythematosus. The American Journal of Medicine 2006 119 8 700 706 2-s2.0-33746406072 10.1016/j.amjmed.2005.11.034 (Pubitemid 44128446)
9. Ippolito A., Petri M., An update on mortality in systemic lupus erythematosus. Clinical and Experimental Rheumatology 2008 26 S72 S79
10. Bertsias G., Boumpas D. T., Update on the management of lupus nephritis: let the treatment fit the patient. Nature Clinical Practice Rheumatology 2008 4 9 464 472 2-s2.0-51149105272 10.1038/ncprheum0896
11. Kiani A. N., Petri M., Quality-of-life measurements versus disease activity in systemic lupus erythematosus. Current Rheumatology Reports 2010 12 4 250 258 2-s2.0-77955982546 10.1007/s11926-010-0114-1
12. Liao Y. N., Liu C. S., Tsai T. R., Hung Y. C., Chang S. J., Lin H. L., Chen Y. C., Lai H. M., Yu S. F., Chen C. J., Preliminary study of a traditional Chinese medicine formula in systemic lupus erythematosus patients to taper steroid dose and prevent disease flare-up. The Kaohsiung Journal of Medical Sciences 2011 27 7 251 257 2-s2.0-79960370826 10.1016/j.kjms.2011.03.001
13. Zhang B. Y., Dong J. H., Zhou Z. Y., Traditional Chinese Internal Medicine 1985 Shanghai, China Shang Hai Science and Technology Press
14. Chen D. P., Wong C. K., Leung P. C., Anti-inflammatory activities of Chinese herbal medicine sinomenine and Liang Miao San on tumor necrosis factor- activated human fibroblast-like synoviocytes in rheumatoid arthritis. Journal of Ethnopharmacologyvol 2011 137 1 457 468
15. Chinese Pharmacopoeia Commission, Pharmacopoeia of the People's Republic of China 2005 Beijing, China People's Medical Publishing House
16. Xu X. F., Qu H. R., Xiang Z. Y., Effects of Ziyin Jiedu Quyu Decoction on glucocorticoid dosage in systemic lupus erythematosus: a double-blind randomized controlled trial. Shang Hai Journal of Traditional Chinese Medicine 2012 46 1 33 36
17. Li H. H., Lu X. L., An overview of Chinese Medicine in the treatment of systemic lupus erythematosus. Modern Journal of Integrated Traditional Chinese and Western Medicineno 2012 21 36 4100 4102
18. Zhao P. J., Mao J. C., Chen X. J., Efficacy observation on mild to moderate active systemic lupus erythematosus treated with compound Zishenqing formula. World Journal of Integrated Traditional and Western Medicine 2012 7 1 37 39
19. Chen X. J., Gu J. H., Observational study of Zi Shen Qing in the treatment of active systemic lupus erythematosus. Shang Hai Journal of Traditional Chinese Medicine 1999 10 16 18
20. Chen X. J., Gu J. H., Mao J. C., Clinical study of Zi Shen Qing combination with Western medicine in the treatment of systemic lupus erythematosus. Jiang Su Journal of Traditional Chinese Medicine 2009 41 8 26 28
21. Liu S. Q., Chen X. J., Treatment of 62 mild to moderate active systemic lupus erythematosus with Zi Shen Qing formula. Hei Long Jiang Medicine Journal 2010 123 12 224 226
22. Koopman W. J., Arthritis and Allied Conditionsed 1997 13th Baltimore, Md, USA Williams & Wilkins
23. The State Administration of traditional Chinese Medicine of the People's Republic of China, Guidance For Clinical Research of Chinese Herbal Medicine 2002 2002 Beijing, China China Press of Traditional Chinese Medicine
24. The State Administration of traditional Chinese Medicine of the People's Republic of China, Criteria of Diagnosis and Therapeutic Effect of Diseases and Syndromes in Traditional Chinese Medicine 1994 Beijing, China Nanjing University Press
25. Zhou X., Xie R. F., Gu J. H., Use HPLC-MS-MS to determine the astragaloside content of ZSQ granules. Shan Xi Journal of Traditional Chinese Medicine 2008 29 4 490 492
26. Zhou X., Gu J. H., Xie R. F., The qualitative identification and quantitative detection for total paeoniflorin in ZSQ granules. Journal of Hangzhou Teachers College 28 4 265 269
27. Touma Z., Urowitz M. B., Taghavi-Zadeh S., Ibañez D., Gladman D. D., Systemic lupus erythematosus disease activity Index 2000 responder index 50: sensitivity to response at 6 and 12 months. Rheumatology 2012 51 10 1814 1819
28. Yee C. S., Farewell V. T., Isenberg D. A., Griffiths B., Teh L. S., Bruce I. N., Ahmad Y., Rahman A., Prabu A., Akil M., McHugh N., Edwards C., D'Cruz D., Khamashta M. A., Gordon C., The use of systemic lupus erythematosus disease activity index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology 2011 50 5 982 988 2-s2.0-79955126646 10.1093/ rheumatology/keq376 keq376
29. Ibañez D., Gladman D. D., Touma Z., Nikpour M., Urowitz M. B., Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time. The Journal of Rheumatology 2011 38 1 60 63 2-s2.0-78650885005 10.3899/jrheum.100575
30. Smith P. P., Gordon C., Systemic lupus erythematosus: clinical presentations. Autoimmunity Review 2010 10 1 43 45
31. Tseng C. E., Buyon J. P., Kim M., Belmont H. M., Mackay M., Diamond B., Marder G., Rosenthal P., Haines K., Ilie V., Abramson S. B., The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism 2006 54 11 3623 3632 2-s2.0-33750936797 10.1002/art.22198 (Pubitemid 44737174)
32. Esdaile J. M., The efficacy of antimalarials in systemic lupus erythromatosus. Lupus 1993 2 1 S3 S8 2-s2.0-0027453073 (Pubitemid 23103839)
33. Liu S. Q., Chen X. J., The effectiveness of Zi Shen Qing formula on regulation of CD4, CD25 with the mild to moderate active systemic lupus erythematosus patients. Liao Ning Journal of Traditional Chinese Medicine 34 12 1669 1770
34. Whitley E., Ball J., Statistics review 2: samples and populations. Critical Care 2002 6 2 143 148 2-s2.0-0036220848 (Pubitemid 34296343)
35. Bootsma H., Spronk P., Derksen R., Prevention of relapses in systemic lupus erythematosus. The Lancet 1995 345 8965 1595 1599
36. Marmor M. F., Carr R. E., Easterbrook M., Farjo A. A., Mieler W. F., Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the american academy of ophthalmology. Ophthalmology 2002 109 7 1377 1382 2-s2.0-0036288931 10.1016/S0161-6420(02)01168-5 (Pubitemid 34700934)
37. Dörner T., Therapy: hydroxychloroquine in SLE: old drug, new perspectives. Nature Reviews Rheumatology 2010 6 10 11 10.1038/nrrheum.2009.235
38. Ruiz-Irastorza G., Ramos-Casals M., Brito-Zeron P., Khamashta M. A., Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Annals of the Rheumatic Diseases 2010 69 1 20 28 2-s2.0-73449120372 10.1136/ard.2008.101766
39. Chiu S. C., Lai Y. L., Chang H. H., Chang K. H., Chen S. T., Liao H. F., Chen Y. Y., Chen Y. J., The therapeutic effect of modified Yu Ping Feng San on idiopathic sweating in end-stage cancer patients during hospice care. Phytotherapy Research 2009 23 3 363 366 2-s2.0-61449171008 10.1002/ptr.2633
40. Poon P. M. K., Wong C. K., Fung K. P., Fong C. Y. S., Wong E. L. Y., Lau J. T. F., Leung P. C., Tsui S. K. W., Wan D. C. C., Waye M. M. Y., Au S. W. N., Lau C. B. S., Lam C. W. K., Immunomodulatory effects of a traditional Chinese medicine with potential antiviral activity: a self-control study. The American Journal of Chinese Medicine 2006 34 1 13 21 2-s2.0-32544431751 10.1142/S0192415X0600359X (Pubitemid 43231397)
41. Gu J. H., Chen X. J., Animal experimental study on immune regulating function of ZSQ formula. Acta Universitatis Traditionis Medicalis Sinensis Pharmacologiaeque Shanghaino 2001 15 2 44 45
42. Zarkadis I. K., Mastellos D., Lambris J. D., Phylogenetic aspects of the complement system. Developmental and Comparative Immunology 2001 25 8-9 745 762 2-s2.0-0034871736 10.1016/S0145-305X(01)00034-9 (Pubitemid 32782636)
43. Frank M. M., Atkinson J. P., Samter's Immunologic Diseases 2001 6 Philadelphia, Pa, USA Lippincott Williams & Wilkins
44. Chuang Y. P., Wang C. H., Wang N. C., Chang D. M., Sytwu H. K., Modulatory function of invariant natural killer T cells in systemic lupus erythematosus. Clinical and Developmental Immunology 2012 2012 8 478429 10.1155/2012/478429
45. Gu J. H., Chen X. J., Observation on compound Zishenqing on peripheral blood mononuclear Cell (PBMC) of active SLE by serum pharmacology. Shan Dong Journal of Traditional Chinese Medicine 2007 25 1 47 51
46. Yang Z. Z., Grote D. M., Ziesmer S. C., Soluble IL-2R facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood 2011 118 10 2809 2820
47. El-Shafey E. M., El-Nagar G. F., El-Bendary A. S., Sabry A. A., Selim A. G., Serum soluble interleukin-2 receptor alpha in systemic lupus erythematosus. Iranian Journal of Kidney Diseases 2008 2 2 80 85 2-s2.0-66149087704
48. Luijten R. K., Fritsch-Stork R. D., Bijlsma J. W., Derksen R. H., The use of glucocorticoids in Systemic Lupus Erythematosus. After 60 years still more an art than science. Autoimmunity Review 2012 12 5 617 628 10.1016/j.autrev. 2012.12.001
49. Franchin G., Diamond B., Pulse steroids: how much is enough? Autoimmunity Reviews 2006 5 2 111 113 2-s2.0-31144467045 10.1016/j.autrev.2005.08.003 (Pubitemid 43129538)
50. Illei G. G., Austin H. A., Crane M., Collins L., Gourley M. F., Yarboro C. H., Vaughan E. M., Kuroiwa T., Danning C. L., Steinberg A. D., Klippel J. H., Balow J. E., Boumpas D. T., Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Annals of Internal Medicine 2001 135 4 248 257 2-s2.0-0035928643 (Pubitemid 32799338)
51. Petri M., Monitoring systemic lupus erythematosus in standard clinical care. Best Practice and Research 2007 21 4 687 697 2-s2.0-34547485022 10.1016/j.berh.2007.01.003 (Pubitemid 47163598)
52. Thamer M., Hernán M. A., Zhang Y., Cotter D., Petri M., Prednisone, lupus activity, and permanent organ damage. The Journal of Rheumatology 2009 36 3 560 564 2-s2.0-65649133584 10.3899/jrheum.080828